Porosome Therapeutics, Inc., [https://www.porosome.com] the holding company of Porosome.AI, “owns” the entire Porosome space. Using cryo-EM, associated molecular and biochemical approached and AI, Porosome.AI maps the atomic structure of the porosome and thus allows precision identification, engineer and target peptide and small molecule drugs to modulate secretory disorder, thereby treating the disease. As noted, Porosome.AI has already discovered several small molecule drug candidates deemed safe by the FDA. Porosome.AI is transformative because it enables both the molecular-level understanding of the porosome nanomachine and its use as a platform for the design and development of new and novel drugs and therapies. Porosome.AI is already partnering with two major biotech AI companies.